Tomos Ioannis, Kallieri Maria, Papaioannou Andriana I, Stagaki Eleni, Raptakis Thomas, Karakatsani Anna, Korkonikitas Panagiotis, Manali Effrosyni D, Karageorgou Vagia, Mplizou Myrto, Vlami Katerina, Loukides Stelios, Papiris Spyros
2nd Pulmonary Medicine Department, 'ATTIKON' University Hospital, Medical School, National and Kapodistrian University of Athens, Greece.
Department of Cardiology, "Agia Olga" Hospital, Athens, Greece.
Respir Med Case Rep. 2022 Nov 24;40:101782. doi: 10.1016/j.rmcr.2022.101782. eCollection 2022.
Antiplatelet therapy including aspirin and thienopyridine agents (such as clopidogrel, prasugrel and ticagrelor) are often used in patients with coronary disease. Pulmonary hemorrhage due to antiplatelet therapy although very rare, when excessive, is a life-threatening event. So far, there is lack of specific guidelines for the management of these patients. We report a case series of 5 patients receiving antiplatelet therapy who were admitted to the hospital due to pulmonary hemorrhage related to antiplatelet therapy. We also propose an algorithm on the management of these patients taking into consideration the balance between thrombotic and bleeding risk and the severity of the hemorrhage.
抗血小板治疗，包括阿司匹林和噻吩吡啶类药物（如氯吡格雷、普拉格雷和替格瑞洛）常用于冠心病患者。抗血小板治疗导致的肺出血虽然非常罕见，但一旦过量，就是危及生命的事件。到目前为止，缺乏针对这些患者管理的具体指南。我们报告了一组5例接受抗血小板治疗的患者，他们因与抗血小板治疗相关的肺出血而入院。我们还提出了一种针对这些患者的管理算法，同时考虑血栓形成和出血风险之间的平衡以及出血的严重程度。
